Trailing-twelve-month (TTM) revenue is $3.27 Million with a year-over-year growth of +27.78%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $784,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $893,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-30 |
| Q1 FY2026Period ended 2026-03-31 | $724,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12 |
| Q2 FY2026Period ended 2026-06-30 | $869,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $3,270,000 |
Current P/S: $23,380,211 market capitalization ÷ $3,270,000 TTM revenue = 7.15x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $869000.00.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T21:38:53.167Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2023-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20182018-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD |
|---|---|---|---|---|
| Annovera | N/A | $38M | N/A | N/A |
| IMVEXXY R | $1M | N/A | N/A | N/A |
| License | N/A | $1M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|
| Non-US | $638,000 | $1M |
| UNITED STATES | $1M | $2M |
$3.27M
$3.27 Million
+27.78%
vs. $2.56M a year ago (TTM)
(47.86%)
5 Year compound annual growth rate
1 Year
+27.78%
3 Year
+11.50%
5 Year
(47.86%)
10 Year
(16.63%)
15 Year
+8.11%
20 Year
+6.18%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $3.02M | +$1.26M | +71.61% |
| 2024 | $1.76M | +$459,000 | +35.25% |
| 2023 | $1.30M | ($68.66M) | (98.14%) |
| 2022 | $69.96M | +$67.39M | +2619.12% |
| 2021 | $2.57M | ($62.30M) | (96.03%) |
| 2020 |
TTM Growth
+27.78%
3-Year CAGR
+11.50%
5-Year CAGR
(47.86%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T21:38:53.167Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| $1M |
| Prescription Vitamins | $15M | $6M | N/A | N/A |
|---|
| Product | N/A | $86M | N/A | N/A |
|---|
| $64.87M |
| +$15.22M |
| +30.67% |
| 2019 | $49.65M | +$33.55M | +208.38% |
| 2018 | $16.10M | ($678,253) | (4.04%) |
| 2017 | $16.78M | ($2.58M) | (13.32%) |
| 2016 | $19.36M | ($786,448) | (3.90%) |
